journal article·2025-11-12Open access

Current Models of Transcatheter Aortic Valves: Comparative Analysis of Design, Clinical Outcomes and Development Prospects

Konstantin Kozyr, Bogachev-Prokophiev Alexander, Oleg Krestyaninov, Ravil Sharifulin, Anton Zalesov, Alexandra Mochalova, Bashir Tsaroev, Svetlana Tamkovich

Applied Sciences· Volume 15· Issue 22

Abstract

Objectives: Transcatheter aortic valve implantation (TAVI) has become the standard of care for severe aortic stenosis across all surgical risk categories. Continuous innovation in prosthesis technology necessitates a comprehensive and clinically oriented analysis of contemporary TAVI systems to guide device selection and understand evolving trends. This review aims to provide a practical, device-specific decision-making framework for TAVI prosthesis selection, synthesizing the latest evidence (2023–2025) to address the challenge of individualized choice in an era of device proliferation. We conducted a detailed review of current TAVI models from leading manufacturers (Medtronic, Abbott, Boston Scientific, Biotronik, etc.), examining their technical specifications, design innovations, and data from recent international clinical trials and registries. A comparative analysis was performed based on key parameters: delivery profile, resheathability/repositionability, sealing mechanisms, hemodynamic performance, and complication rates. Modern TAVI prostheses demonstrate significant advancements. Self-expanding nitinol frames offer superior adaptability and lower profiles (as low as 14 Fr). Innovations in sealing technology have drastically reduced the incidence of moderate-to-severe paravalvular leak (PVL) to below 2–3%. Supra-annular leaflet designs provide superior hemodynamics. Clinical outcomes show excellent 30-day mortality rates (1.1–2.0%) and durability estimates of 10–15 years. Variation exists between devices in rates of permanent pacemaker implantation and coronary access. The current generation of TAVI prostheses represents a mature technology offering high safety and efficacy. The key development vectors are focused on further device miniaturization, enhancing long-term durability, and expanding indications. This analysis provides a novel, clinically oriented comparison that moves beyond technical specifications to guide optimal device selection based on specific patient anatomy and clinical characteristics.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cardiac Valve Diseases and Treatments · Aortic Disease and Treatment Approaches · Infective Endocarditis Diagnosis and Management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

E.N. Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, 630055 Novosibirsk, Russia

Institute of Medicine and Medical Technologies, Novosibirsk State University, 630090 Novosibirsk, Russia

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia

Funding

Russian Science Foundation

References (51)

Show source-provided references
1. Guidelines on the management of valvular heart disease (version 2012)10.1093/eurheartj/ehs109 ↗
2. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease10.1016/S0195-668X(03)00201-X ↗
3. Development of transcatheter aortic valve implantation (TAVI): A 20-year odyssey10.1016/j.acvd.2012.01.005 ↗
4. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery10.1056/NEJMoa1008232 ↗
5. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description10.1161/01.CIR.0000047200.36165.B8 ↗
6. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients10.1056/NEJMoa1814052 ↗
7. Recently patented transcatheter aortic valves in clinical trials
8. New-generation TAVI devices: Description and specifications10.4244/EIJV10SUA13 ↗
9. The SAVI-TF registry: 1-year outcomes of the European post-market registry using the ACURATE neo™ transcatheter heart valve under real-world conditions in 1000 patients
10. The ACURATE neo transcatheter heart valve: A comprehensive review
11. TAVI with current CE-marked devices: Strategies for optimal sizing and valve delivery10.4244/EIJV12SYA6 ↗
12. The ACURATE neo Transcatheter Heart Valve: A Comprehensive Analysis of Predictors of Procedural Outcome10.1016/j.jcin.2018.04.039 ↗
13. A Bicuspid Aortic Valve Imaging Classification for the TAVR Era10.1016/j.jcmg.2015.12.022 ↗
14. Two-year outcomes after transcatheter or surgical aortic-valve replacement10.1056/NEJMoa1200384 ↗
15. Transcatheter aortic valve implantation with the Edwards SAPIEN 3 valve: Impact of balloon-expandable technology on clinical outcomes
16. Transcatheter aortic-valve replacement with a self-expanding prosthesis10.1056/NEJMoa1400590 ↗
17. Treatment of aortic stenosis with a self-expanding transcatheter valve: The International Multi-centre ADVANCE Study10.1093/eurheartj/ehu162 ↗
18. Degeneration mechanisms and advancements in optimization for preparation and crosslinking strategy of pericardium-based bioprosthetic heart valves10.1016/j.actbio.2025.05.062 ↗
19. (2021). Cardiovascular Implants—Cardiac Valve Prostheses—Part 3: Heart Valve Substitutes Implanted by Transcatheter Techniques (Standard No. *ISO 5840-3:2021*).
20. EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease10.1016/j.echo.2011.07.003 ↗
21. Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: A longitudinal study of echocardiography parameters in cohort A of the PARTNER trial (placement of aortic transcatheter valves)10.1016/j.jacc.2013.02.087 ↗
22. Three-Year Outcomes with a Supra-Annular, Self-Expanding Bioprosthesis and a Pericardial Wrap-The FORWARD PRO Study
23. Paravalvular leak after transcatheter aortic valve replacement: The new Achilles’ heel? A comprehensive review of the literature10.1016/j.jacc.2012.08.1039 ↗
24. Three-Year Outcomes from the Evolut Low Risk TAVR Trial10.1016/j.jcin.2024.05.017 ↗
25. Depth of valve implantation, conduction disturbances and pacemaker implantation with CoreValve and CoreValve Accutrak system: An observational study10.1016/j.ijcard.2014.07.092 ↗
26. New conduction abnormalities after TAVI--frequency and causes10.1038/nrcardio.2012.58 ↗
27. Transcatheter versus surgical aortic-valve replacement in high-risk patients10.1056/NEJMoa1103510 ↗
28. 30-Day Outcomes of the Navitor Transcatheter Heart Valve in the NAVIGATE TAVR Study
29. Early Safety and Efficacy of the ACURATE neo2 Transcatheter Heart Valve: 30-Day Outcomes from the NEOPRO 2 Registry
30. BIOTRONIK Announces Successful First Implantations of Resheathable Transcatheter Aortic Valve (2025, February 01). Building Better Healthcare. Available online: https://www.buildingbetterhealthcare.com/news/article_page/BIOTRONIK_announces_successful_first_implantations_of_Resheathable_Transcatheter_Aortic_Valve/206321.
31. Safety and Performance Outcomes Published for Biotroniks Biovalve Tavr Device (2025, February 01). CI Today. Available online: https://citoday.com/news/safety-and-performance-outcomes-published-for-biotroniks-biovalve-tavr-device.
32. From an Unfolding Emergency Treatment to a Universal Shift in Therapy: The Story of Transcatheter Aortic Valve Implantation (TAVI)10.31083/j.rcm2310349 ↗
33. ResearchGate (2025, February 01). Transcatheter Aortic Valve Replacement Technique and Current Approaches. Available online: https://www.researchgate.net/publication/375324031_Transcatheter_Aortic_Valve_Replacement_Technique_and_Current_Approaches.
34. Transcatheter aortic valve implantation in bicuspid anatomy10.1038/nrcardio.2014.161 ↗
35. Transfemoral aortic valve implantation using a self-expanding transcatheter heart valve without pre-dilation10.1016/j.ijcard.2017.05.092 ↗
36. Supra-annular sizing for transcatheter valve implantation in bicuspid aortic stenosis
37. 30-Day and 1-Year Outcomes with HYDRA Self-Expanding Transcatheter Aortic Valve: The Hydra CE Study10.1016/j.jcin.2021.09.004 ↗
38. Transapical implantation of a second-generation transcatheter heart valve in patients with noncalcified aortic regurgitation10.1016/j.jcin.2013.01.138 ↗
39. Transapical transcatheter aortic valve implantation using the JenaValve™ system: 30-day results of a multicentre registry10.1093/ejcts/ezs129 ↗
40. JenaValve Technology (2025, February 01). Company Information, 2024. Available online: https://www.jenavalve.com/.
41. MicroPort CardioFlow (2025, February 01). VitaFlow™ TAVI System Clinical Results, 2023. Available online: https://www.microport.com/cardioflow/en/product/vitaflow.
42. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document10.1093/eurheartj/ehs255 ↗
43. Thirty-Day and One-Year Outcomes for the Navitor Transcatheter Heart Valve in the International PORTICO NG Study
44. In-Hospital Outcomes of Evolut FX vs. Evolut PRO+ in the J-TVT Registry
45. Early Experience with the Evolut FX versus Evolut PRO+ Transcatheter Aortic Valve Systems10.1016/j.carrev.2023.06.003 ↗
46. Review of the Evolut PRO and FX Systems for Transcatheter Aortic Valve Implantation10.1080/17434440.2022.2113386 ↗
47. Double crosslinking decellularized bovine pericardium of dialdehyde chondroitin sulfate and zwitterionic copolymer for bioprosthetic heart valves with enhanced antithrombogenic, anti-inflammatory and anti-calcification properties10.1039/D4TB00074A ↗
48. Transcatheter aortic valve replacement with the St. Jude Medical Portico valve: First-in-human experience10.1016/j.jacc.2012.02.045 ↗
49. Hu, C. (2025, January 24–26). NEUSoft™ Medical Thermoplastic Polyurethane for In-Vivo solutions and Lubricious Catheters. Proceedings of the Medtec China 2025 Conference Program, Shanghai, China.
50. Vervust, T., and Wen, Z. (2025, January 24–26). Advancing Biomedical Innovation with X-Pure Ultra-Pure Gelatin. Proceedings of the Medtec China 2025 Conference Program, Shanghai, China.
51. Xing, Y. (2025, January 24–26). The Applications of Ultra-high Precision 3D Printing Technology and Materials in the Medical Industry. Proceedings of the Medtec China 2025 Conference Program, Shanghai, China.